Prognostic Value of MTV and TLG of ¹⁸F-FDG PET in Patients with Stage I and II Non-Small-Cell Lung Cancer: a Meta-Analysis

Table 1

Features of included studies.

Study	Year	Country	Study period	Follow-up duration (months)	Median age (range), years	No. of patients	TNM staging	End points	Study design	Histology	Treatment
Suman et al.	2020	Japan	2010.6–2016.10	44.8	73 (53–85)	39	I	OS PFS	Retro	Adenocarcinoma; Squamous cell carcinoma	Radiotherapy
Domachevsky et al.	2015	Israel	2007–2012	60	68.7 ± 8.9	181	I-II	OS	Retro	Adenocarcinoma; Squamous cell carcinoma; Mixed/sarcomatoid; Bronchioloalveolar; Adenocarcinoma with bronchioloalveolar	Surgery
Seong et al.	2015	Korea	2006.2–2011.12	36.6	63.03 ± 10.01	248	I	OS	Retro	Adenocarcinoma; Nonadenocarcinoma	Surgery
Seung et al.	2013	Korea	2003.7–2006.12	60	63 (23–83)	529	I-II	OS DFS	Retro	Adenocarcinoma; Squamous cell carcinoma; Large cell carcinoma; Adenosquamous carcinoma; Others	Surgery; Chemotherapy; Radiotherapy
Charles et al.	2013	USA	2007.5–2012.12	25.1	73.3	50	I	OS RFS	Retro	Adenocarcinoma; Squamous cell carcinoma; Others	Radiotherapy
Melloni et al.	2013	Italy	2005.1–2011.1	21 (3–68)	68(40–85)	99	I	PFS	Retro	Adenocarcinoma; Others	Surgery
Abelson et al.	2012	USA	2005.9–2009.12	13.2	80.1(57.6–93.4)	84	I	OS	Retro	Squamous cell carcinoma; Adenocarcinoma; Non-small-cell; Atypia	Radiotherapy
Lin Y et al.	2012	Taiwan	2009.1–2011.2	24(8–36)	63(38–85)	62	I	PFS	Retro	Squamous cell carcinoma; Adenocarcinoma	Surgery

Abbreviations: Retro = retrospective; PFS = progression-free survival; DFS = disease-free survival; RFS = recurrence-free survival; OS = overall survival.